Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily
Brief Summary: Primary objective:

To compare the change in liver fat content and visceral fat mass (cm2) assessed by MRS (Magnetic Resonance Spectroscopy) and MRI (Magnetic Resonance Image), after 26 weeks of treatment with insulin detemir once daily or insulin NPH once daily both with metformin in overweight and obese type 2 diabetic subjects.

Secondary objectives:

To compare the two treatments with respect to:

1. Efficacy:

   * MRI: abdominal subcutaneous fat mass(cm2), Calculated Visceral/Subcutaneous Adipose Tissue Ratio.
   * Change in HbA1c from baseline at 12 and 26 weeks of treatment.
   * Change in Fasting plasma glucose from baseline at 12 and 26 weeks of treatment.
   * Weight
   * Waist and hip circumference
2. Safety:

   * Incidence of hypoglycaemia in the 26 weeks of treatment with insulin detemir versus NPH
   * Lipid profile at the start and after 26 weeks of treatment
   * Incidence of Adverse events during the trial
   * Safety profile as measured by laboratory safety parameters (haematology, biochemistry) and physical examination/vital signs before and at the end of treatment


Options:
A: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
B: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine 300 UNT/ML | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neutral protamine hagedorn insulin | Intervention Type: DRUG; Name: Insulin Glargine 300 UNT/ML; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Neutral protamine hagedorn insulin; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A

Answer: A